Document:

Exhibit 10.2 

 

AGREEMENT BY AND BETWEEN REGEN
BIOPHARMA, INC. AND ZANDER THERAPEUTICS, INC.

Dated June 15, 2016

 

WHEREAS, REGEN BIOPHARMA, INC. (“REGEN”)
AND ZANDER THERAPEUTICS, INC. (“ZANDER”) ARE PARTIES TO THAT AGREEMENT DATED JUNE 23, 2015 WITH ZANDER WHEREBY REGEN
GRANTED TO ZANDER AN EXCLUSIVE WORLDWIDE RIGHT AND LICENSE FOR THE DEVELOPMENT AND COMMERCIALIZATION OF CERTAIN INTELLECTUAL PROPERTY
CONTROLLED BY REGEN (“LICENSE AGREEMENT”).

WHEREAS THE LICENSE AGREEMENT OBLIGATES ZANDER TO PAY
TO REGEN A NON-REFUNDABLE PAYMENT OF ONE HUNDRED THOUSAND US DOLLARS ($100,000) ON THE FIRST ANNIVERSARY OF THE EFFECTIVE DATE
OF THE LICENSE AGREEMENT.

WHEREAS REGEN AND ZANDER WISH TO AMEND THE DUE DATE
OF THE AFOREMENTIONED NON-REFUNDABLE PAYMENT OF ONE HUNDRED THOUSAND US DOLLARS ($100,000) ON THE FIRST ANNIVERSARY OF THE EFFECTIVE
DATE OF THE LICENSE AGREEMENT (“FIRST ANNIVERSARY PAYMENT”) .

THEREFORE, IT IS AGREED AS FOLLOWS:

THE FIRST ANNIVERSARY PAYMENT SHALL BE DUE AND PAYABLE
ON JULY 15, 2016.

EACH PARTY HEREBY IS DULY ORGANIZED,
VALIDLY EXISTING AND IN GOOD STANDING UNDER THE LAWS OF THEIR RESPECTIVE JURISDICTION. EACH PARTY HAS THE FULL RIGHT AND POWER
TO ENTER INTO AND PERFORM ITS OBLIGATIONS UNDER THIS AGREEMENT AND EACH HAS DULY AUTHORIZED, EXECUTED AND DELIVERED THIS AGREEMENT
WHICH IS BINDING UPON, AND ENFORCEABLE AGAINST, EACH PARTY IN ACCORDANCE WITH ITS TERMS. TO THE BEST KNOWLEDGE OF EACH PARTY THERE
IS NO ACTION AT LAW OR IN EQUITY, NO ARBITRATION PROCEEDING AND NO ACTION, PROCEEDING, COMPLAINT OR INVESTIGATION BEFORE OR BY
ANY FEDERAL, FOREIGN, STATE OR LOCAL GOVERNMENT OR REGULATORY COMMISSION, AGENCY OR OTHER ADMINISTRATIVE OR REGULATORY BODY OR
AUTHORITY PENDING OR THREATENED AGAINST OR AFFECTING EITHER PARTY ITS OFFICERS, DIRECTORS, BUSINESS OR AFFAIRS THAT WILL AFFECT
THE SET OVER OF THE ASSIGNED PATENT AND THE EQUITABLE CONSIDERATION, AS STATED HEREIN.

ALL QUESTIONS CONCERNING THE CONSTRUCTION,
VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE
INTERNAL LAWS OF THE STATE OF CALIFORNIA, WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH PARTY HEREBY IRREVOCABLY
SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN CALIFORNIA FOR THE ADJUDICATION OF ANY DISPUTE
HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN AND HEREBY IRREVOCABLY WAIVES,
AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF
ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER OR INCONVENIENT VENUE FOR SUCH PROCEEDING. IF EITHER PARTY SHALL
COMMENCE AN ACTION OR PROCEEDING TO ENFORCE ANY PROVISIONS OF THIS AGREEMENT, THEN THE PREVAILING PARTY IN SUCH ACTION OR PROCEEDING
SHALL BE REIMBURSED BY THE OTHER PARTY FOR ITS ATTORNEYS’ FEES AND

    	1 

    	 

    

OTHER COSTS AND EXPENSES INCURRED
WITH THE INVESTIGATION, PREPARATION AND PROSECUTION OF SUCH ACTION OR PROCEEDING.

ALL QUESTIONS CONCERNING THE CONSTRUCTION,
VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE
INTERNAL LAWS OF THE STATE OF CALIFORNIA, WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH PARTY HEREBY IRREVOCABLY
SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN CALIFORNIA FOR THE ADJUDICATION OF ANY DISPUTE
HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN AND HEREBY IRREVOCABLY WAIVES,
AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF
ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER OR INCONVENIENT VENUE FOR SUCH PROCEEDING. IF EITHER PARTY SHALL
COMMENCE AN ACTION OR PROCEEDING TO ENFORCE ANY PROVISIONS OF THIS AGREEMENT, THEN THE PREVAILING PARTY IN SUCH ACTION OR PROCEEDING
SHALL BE REIMBURSED BY THE OTHER PARTY FOR ITS ATTORNEYS’ FEES AND OTHER COSTS AND EXPENSES INCURRED WITH THE INVESTIGATION,
PREPARATION AND PROSECUTION OF SUCH ACTION OR PROCEEDING.

 

	REGEN BIOPHARMA INC. 	ZANDER THERAPEUTICS INC.
	 	 
	By: /s/David R. Koos	By: /s/David R. Koos
	 	 
	David R. Koos	David R. Koos 
	Chairman & CEO 	Chairman & CEOExhibit 10.3 

 

AGREEMENT BY AND BETWEEN REGEN
BIOPHARMA, INC. AND ZANDER THERAPEUTICS, INC.

Dated September 12, 2017

 

WHEREAS, REGEN BIOPHARMA, INC. (“REGEN”)
AND ZANDER THERAPEUTICS, INC. (“ZANDER”) ARE PARTIES TO THAT AGREEMENT DATED JUNE 23, 2015 WITH ZANDER WHEREBY REGEN
GRANTED TO ZANDER AN EXCLUSIVE WORLDWIDE RIGHT AND LICENSE FOR THE DEVELOPMENT AND COMMERCIALIZATION OF CERTAIN INTELLECTUAL PROPERTY
CONTROLLED BY REGEN (“LICENSE AGREEMENT”).

WHEREAS REGEN AND ZANDER WISH TO ADD TO THE INTELLECTUAL
PROPERTY FOR WHICH AN EXCLUSIVE WORLDWIDE RIGHT AND LICENSE FOR THE DEVELOPMENT AND COMMERCIALIZATION HAS BEEN GRANTED TO ZANDER
BY REGEN

THEREFORE IT IS AGREED AS FOLLOWS:

EXHIBIT A OF THE LICENSE AGREEMENT SHALL BE AND READ:

Exhibit A

Any and all intellectual property
controlled by Regen Biopharma, Inc. exclusive of trademarks 

 

EACH PARTY HEREBY IS DULY ORGANIZED,
VALIDLY EXISTING AND IN GOOD STANDING UNDER THE LAWS OF THEIR RESPECTIVE JURISDICTION. EACH PARTY HAS THE FULL RIGHT AND POWER
TO ENTER INTO AND PERFORM ITS OBLIGATIONS UNDER THIS AGREEMENT AND EACH HAS DULY AUTHORIZED, EXECUTED AND DELIVERED THIS AGREEMENT
WHICH IS BINDING UPON, AND ENFORCEABLE AGAINST, EACH PARTY IN ACCORDANCE WITH ITS TERMS. TO THE BEST KNOWLEDGE OF EACH PARTY THERE
IS NO ACTION AT LAW OR IN EQUITY, NO ARBITRATION PROCEEDING AND NO ACTION, PROCEEDING, COMPLAINT OR INVESTIGATION BEFORE OR BY
ANY FEDERAL, FOREIGN, STATE OR LOCAL GOVERNMENT OR REGULATORY COMMISSION, AGENCY OR OTHER ADMINISTRATIVE OR REGULATORY BODY OR
AUTHORITY PENDING OR THREATENED AGAINST OR AFFECTING EITHER PARTY ITS OFFICERS, DIRECTORS, BUSINESS OR AFFAIRS THAT WILL AFFECT
THE SET OVER OF THE ASSIGNED PATENT AND THE EQUITABLE CONSIDERATION, AS STATED HEREIN.

ALL QUESTIONS CONCERNING THE CONSTRUCTION,
VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE
INTERNAL LAWS OF THE STATE OF CALIFORNIA, WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH PARTY HEREBY IRREVOCABLY
SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN CALIFORNIA FOR THE ADJUDICATION OF ANY DISPUTE
HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN AND HEREBY IRREVOCABLY WAIVES,
AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF
ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER OR INCONVENIENT VENUE FOR SUCH PROCEEDING. IF EITHER PARTY SHALL
COMMENCE AN ACTION OR PROCEEDING TO ENFORCE ANY PROVISIONS OF THIS AGREEMENT, THEN THE PREVAILING PARTY IN SUCH ACTION

    	 	1	 

     

    

OR PROCEEDING SHALL BE REIMBURSED
BY THE OTHER PARTY FOR ITS ATTORNEYS’ FEES AND OTHER COSTS AND EXPENSES INCURRED WITH THE INVESTIGATION, PREPARATION AND
PROSECUTION OF SUCH ACTION OR PROCEEDING.

ALL QUESTIONS CONCERNING THE CONSTRUCTION,
VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE
INTERNAL LAWS OF THE STATE OF CALIFORNIA, WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH PARTY HEREBY IRREVOCABLY
SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN CALIFORNIA FOR THE ADJUDICATION OF ANY DISPUTE
HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN AND HEREBY IRREVOCABLY WAIVES,
AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF
ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER OR INCONVENIENT VENUE FOR SUCH PROCEEDING. IF EITHER PARTY SHALL
COMMENCE AN ACTION OR PROCEEDING TO ENFORCE ANY PROVISIONS OF THIS AGREEMENT, THEN THE PREVAILING PARTY IN SUCH ACTION OR PROCEEDING
SHALL BE REIMBURSED BY THE OTHER PARTY FOR ITS ATTORNEYS’ FEES AND OTHER COSTS AND EXPENSES INCURRED WITH THE INVESTIGATION,
PREPARATION AND PROSECUTION OF SUCH ACTION OR PROCEEDING.

 

	REGEN BIOPHARMA INC. 	ZANDER THERAPEUTICS INC.
	 	 
	By: /s/David Koos	By: /s/David Koos
	 	 
	David R. Koos	David R. Koos 
	Chairman & CEO 	Chairman & CEOExhibit
10.4

 

LINE
OF CREDIT PROMISSORY NOTE

 

$500,000
Date: September 6, 2016

 

FOR
VALUE RECEIVED, Zander Therapeutics, Inc., ("Borrower") promises to pay to the order of Entest Biomedical, Inc.
("Lender"), a Nevada Corporation, the principal sum of Five Hundred Thousand Dollars ($500,000), or so much thereof
as may be disbursed to, or for the benefit of the Borrower by Lender in Lender's sole and absolute discretion. It is the intent
of the Borrower and Lender hereunder to create a line of credit agreement between Borrower and Lender whereby Borrower may borrow
up to $ 500,000 from Lender. This agreement shall also be the terms and conditions of any
and all borrowed amounts outstanding as of this date.

 

INJEREST
& PRINCIPAL: The unpaid principal of this line of credit shall bear simple
interest at the rate of ten percent ( I0%) per annum. Interest shall be calculated based on the principal balance as may be adjusted
from time to time to reflect additional advances or payments made hereunder. Principal balance and accrued interest shall become
due and payable in whole or in part at the demand of the Lender.

 

REPRESENTATIONS
AND WARRANTIES OF BORROWER

 

Borrower
(a) is a corporation duly formed, validly existing and in good standing under the laws of the State of Nevada and (b) has all
requisite power and authority, and has all governmental licenses, authorizations, consents and approvals necessary to execute
and deliver this Agreement and to consummate the transactions contemplated by this Agreement.

 

None
of the execution, delivery and performance of this Agreement by Borrower, or the consummation of the transactions contemplated
hereby and thereby (a) constitute or will constitute a violation of the organizational documents of Borrower, (b) constitutes
or will constitute a breach or violation of, or a default (or an event which, with notice or lapse of time or both, would constitute
such a default) under, any indenture, mortgage, deed of Borrower, loan agreement, lease or other agreement or instrument to which
Borrower is a party or by which Borrower or any of its properties may be bound

 

BORROWER:

 

 

By:
/s/David Koos

David Koos Chairman & CEO Zander Therapeutics Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]